Royalty Pharma PLC at Citi BioPharma Conference Transcript
So I think we're ready to start. Delighted to introduce the management from Royalty Pharma. And unusually, I've worked with both at two separate organizations during my career. So starting on the far left was my former counterpart at Citi, Chris Hite, who is now Vice Chairman of Royalty Pharma. And the gentlemen next to him, who I worked with when I was at another house, I won't mention, is Marshall Urist, who is the Head of Research and Investments at Royalty Pharma. So great to have you both here.
To the audience if you have got any questions that you'd like to ask, just raise a hand and if I'm not blinded by the light I will try and take them.
Questions & Answers
So just maybe to start off, look, the obvious place to start is the share price right? And it is below the IPO, it's obviously, probably about half where it was at its highs. In terms of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |